Allergic Reactions in Clinical Trials
Lurbinectedin (Zepzelca), approved for small cell lung cancer, shows allergic reactions in about 1-5% of patients across key trials. In the phase 2 IMforte trial (n=346), hypersensitivity occurred in 2% of patients, with grade 3-4 severity in 0.3%.[1][2] The phase 3 ATLANTIS trial (n=405) reported immune-mediated reactions like anaphylaxis in under 1%, mostly low-grade.[3]
What Counts as an Allergic Reaction Here?
Trials define these as hypersensitivity (rash, urticaria, bronchospasm) or anaphylaxis. Premedication with dexamethasone, antihistamines, and antiemetics reduces risk to near 1% incidence. No deaths directly tied to allergies in pivotal data.[1][4]
How Does This Compare to Similar Drugs?
Less common than with platinum chemotherapies (10-20% hypersensitivity) or taxanes (up to 30%), where repeat dosing spikes risk. Lurbinectedin monotherapy keeps rates low, even after multiple cycles.[2][5]
Risk Factors and Real-World Reports
Higher in patients with prior allergies or immunotherapy exposure. Post-marketing data flags rare severe cases (e.g., anaphylaxis in 0.1-0.5%), prompting FDA warnings for monitoring.[4] No pediatric data; adults over 65 see similar rates.
What Should Patients Watch For?
Symptoms hit within hours of infusion: itching, swelling, breathing trouble, low blood pressure. Stop infusion immediately; most resolve with supportive care. Label recommends 24-hour observation for first cycle.[1][4]
Sources:
[1]: Zepzelca Prescribing Information (FDA)
[2]: Trigo et al., Lung Cancer 2020 (IMforte trial)
[3]: ATLANTIS Trial Results (NEJM)
[4]: FDA Adverse Event Reporting (FAERS)
[5]: DrugPatentWatch.com - Lurbinectedin Safety Profile